Choose Your Country or Region

Nivolumab (anti-PD-1)

Synonyms: BMS-936558, ONO-4538, MDX-1106

Catalog No.A2002 Purity:99%

Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.

Nivolumab (anti-PD-1) Chemical Structure

Selleck's Nivolumab (anti-PD-1) has been cited by 76 publications

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 7.28mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective PD-1/PD-L1 Inhibitors

Name	Citation	PD-1/PD-L1 interaction	PD-1	PD-1/PD-L1
GS-4224	0	++++		++++
INCB086550	1	++		++
BMS-1001	0	+		+
BMS-1166	5	+++
PD-1/PD-L1 Inhibitor 3	13	+++
BMS-1	12	++
BMS202	23	+
CA-170 (AUPM-170)			✔
SR 0987		✔		IL17,RORγt
Spartalizumab (anti-PD-1)		✔
Camrelizumab (anti-PD-1)		✔
AUNP-12			✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description

Features

Human IgG4

Targets

PD-1/PD-L1 interaction ^[2] (Cell-free assay)	PD-1/PD-L2 interaction ^[2] (Cell-free assay)
2.52 nM	2.59 nM

In Vitro
In vitro	The cell binding ratio of ¹²⁵I-Nivolumab and ¹²⁵I-Nivolumab-DTPA to PD-1 is 13.78 ± 2.90% and 10.22 ± 2.62%, respectively. Conjugating of DTPA does not affect targeting of Nivolumab to PD-1 in vitro.^[1]
Cell Research:	Splenocytes were isolated from the spleens obtained from humanized PD-1 over-expressing mice following standard protocol. ¹²⁵I labeled Nivolumab and Nivolumab-DTPA, respectively. To perform co-culture, ¹²⁵I-Nivolumab and ¹²⁵I-Nivolumab-DTPA (0.37 MBq/µg) were added to the freshly isolated splenocytes (1×10⁶ cells) grown in 6-well plates, respectively. After incubation for 12 h at 4°C, cells were collected after rinsing three times with PBS. ¹²⁵I radioactivity was determined in a gamma counter to evaluate their binding efficiency to PD-1.

In Vitro

In vitro

The cell binding ratio of ¹²⁵I-Nivolumab and ¹²⁵I-Nivolumab-DTPA to PD-1 is 13.78 ± 2.90% and 10.22 ± 2.62%, respectively. Conjugating of DTPA does not affect targeting of Nivolumab to PD-1 in vitro.^[1]

Cell Research:

Splenocytes were isolated from the spleens obtained from humanized PD-1 over-expressing mice following standard protocol. ¹²⁵I labeled Nivolumab and Nivolumab-DTPA, respectively. To perform co-culture, ¹²⁵I-Nivolumab and ¹²⁵I-Nivolumab-DTPA (0.37 MBq/µg) were added to the freshly isolated splenocytes (1×10⁶ cells) grown in 6-well plates, respectively. After incubation for 12 h at 4°C, cells were collected after rinsing three times with PBS. ¹²⁵I radioactivity was determined in a gamma counter to evaluate their binding efficiency to PD-1.

In Vivo
In vivo	In SPECT images, lesions with high ^99mTc-DTPA-nivolumab uptake and relatively clear background are shown at 6 h. Thereafter, the suspected intestinal thickening in Gd-free T1WI is observed at 2 h after the addition of Gd-DTPA-nivolumab.^[1]
Animal Research	Animal Models: CRC mouse models (highly expressed human PD-1 antigen) Dosages: 11.1 MBq/10 μg Administration: i.v. Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883027/

References
[1] Li D, et al. Front Bioeng Biotechnol. 2022 Feb 14;10:839756.

References

[1] Li D, et al. Front Bioeng Biotechnol. 2022 Feb 14;10:839756.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	946414-94-4
Isotype	Human IgG4
Source	CHO cells
Formulation	100 mM Pro-Ac, 20 mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.